← Search & browse all drugs
NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › PARASYMPATHOMIMETICS › Other parasympathomimetics
choline alfoscerate
N07AX02
Forms & Strengths
- Oral capsules: 400 mg
- Oral solution: 1000 mg / 10 mL
- Solution for injection: 1000 mg / 4 mL
Adult Dosing
- Cognitive impairment/Dementia: 400 mg orally three times daily
- Acute stroke/Transient ischemic attack: 1000 mg/day intramuscularly or intravenously for 4 weeks
- Maintenance post-stroke: 400 mg orally three times daily for up to 6 months
Pediatric Dosing
- Safety and efficacy not established in pediatric populations
Indications
- Cognitive decline associated with cerebral aging
- Dementia of Alzheimer's type and multi-infarct dementia
- Secondary therapy in acute cerebrovascular accident and transient ischemic attacks
Mechanism of Action
- Central cholinergic agonist and precursor of acetylcholine synthesis
- Increases phospholipid biosynthesis in neuronal membranes, improving neuroplasticity
- Enhances neurotransmitter release and receptor sensitivity in the central nervous system
Contraindications
- Known hypersensitivity to choline alfoscerate
- Severe renal or hepatic impairment (caution advised)
- Pregnancy and lactation due to insufficient safety data
Adverse Reactions
- Heartburn, nausea, and gastric pain
- Transient confusion or agitation in elderly patients
- Insomnia or headache
- Injection site pain and phlebitis (parenteral administration)
Drug Interactions
- Anticholinergic agents may antagonize the therapeutic effects of central cholinergic precursors
- Synergistic effects possible with other cholinomimetic drugs
- No major clinically significant pharmacokinetic drug-drug interactions reported
Curated Content: Needs Vetting Before Put to Clinical Use